JPWO2022072820A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022072820A5 JPWO2022072820A5 JP2023520066A JP2023520066A JPWO2022072820A5 JP WO2022072820 A5 JPWO2022072820 A5 JP WO2022072820A5 JP 2023520066 A JP2023520066 A JP 2023520066A JP 2023520066 A JP2023520066 A JP 2023520066A JP WO2022072820 A5 JPWO2022072820 A5 JP WO2022072820A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- cell
- carcinoma
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063086972P | 2020-10-02 | 2020-10-02 | |
| US63/086,972 | 2020-10-02 | ||
| PCT/US2021/053159 WO2022072820A1 (en) | 2020-10-02 | 2021-10-01 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023548745A JP2023548745A (ja) | 2023-11-21 |
| JP2023548745A5 JP2023548745A5 (https=) | 2024-10-08 |
| JPWO2022072820A5 true JPWO2022072820A5 (https=) | 2024-10-08 |
| JP7846686B2 JP7846686B2 (ja) | 2026-04-15 |
Family
ID=80951026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520066A Active JP7846686B2 (ja) | 2020-10-02 | 2021-10-01 | 皮下投与のための（ｓ）－イソプロピル２－（（ｓ）－２－アセトアミド－３－（１ｈ－インドール－３－イル）プロパンアミド）－６－ジアゾ－５－オキソヘキサノエートを含む凍結乾燥組成物およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230372294A1 (https=) |
| EP (1) | EP4221842A4 (https=) |
| JP (1) | JP7846686B2 (https=) |
| CN (1) | CN116601140A (https=) |
| WO (1) | WO2022072820A1 (https=) |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| US20100069340A1 (en) * | 2008-09-11 | 2010-03-18 | Wyeth | Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| JP4965623B2 (ja) | 2009-09-30 | 2012-07-04 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| US8916709B2 (en) * | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CA2916638C (en) | 2012-07-31 | 2021-01-12 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
| EA037554B1 (ru) | 2013-03-15 | 2021-04-13 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Анти-lag-3 связывающие белки |
| NZ718821A (en) | 2013-09-11 | 2022-07-01 | Medimmune Ltd | Anti-b7-h1 antibodies for treating tumors |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| EP3328374A4 (en) * | 2015-07-31 | 2019-03-13 | The Johns Hopkins University | GLUTAMINANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITES |
| CA2994165A1 (en) * | 2015-07-31 | 2017-02-09 | The Johns Hopkins University | Methods for cancer and immunotherapy using glutamine analogues, including don |
| AU2016302940B2 (en) | 2015-07-31 | 2021-02-04 | The Johns Hopkins University | Prodrugs of glutamine analogs |
| SG11202107317WA (en) * | 2019-01-18 | 2021-08-30 | Dracen Pharmaceuticals Inc | Combinaton therapy with a don prodrug and an immune checkpoint inhibitor |
| JP2022519574A (ja) * | 2019-02-11 | 2022-03-24 | ドラセン ファーマシューティカルズ インコーポレイテッド | Ｌ－グルタミン酸からｄｏｎプロドラッグを調製する方法 |
| US11760723B2 (en) | 2019-02-11 | 2023-09-19 | Dracen Pharmaceuticals, Inc. | Method of preparing a DON prodrug from L-pyroglutamic acid |
-
2021
- 2021-10-01 JP JP2023520066A patent/JP7846686B2/ja active Active
- 2021-10-01 US US18/247,516 patent/US20230372294A1/en active Pending
- 2021-10-01 CN CN202180080291.8A patent/CN116601140A/zh active Pending
- 2021-10-01 WO PCT/US2021/053159 patent/WO2022072820A1/en not_active Ceased
- 2021-10-01 EP EP21876588.1A patent/EP4221842A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272697B2 (en) | A polymorphic form of TG02 | |
| JP2019509354A5 (https=) | ||
| JP2015533796A5 (https=) | ||
| JP2017528460A5 (https=) | ||
| JP2003518510A (ja) | 癌治療におけるヒアルロン酸 | |
| JPWO2021188948A5 (https=) | ||
| Zhu et al. | Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration | |
| JP2017526706A5 (https=) | ||
| CN116492461A (zh) | 棕榈酰化的抑制剂与parp抑制剂在治疗肿瘤中的应用 | |
| JPWO2022072820A5 (https=) | ||
| JP2023082028A (ja) | Ｓｅｔｄ２を阻害することにより癌を処置する方法 | |
| Mousavia et al. | Response to neoadjuvant chemotherapy with paclitaxel and cisplatin in locally advanced cervical cancer. | |
| Nagano et al. | Long-term outcome after multidisciplinary approach for leptomeningeal carcinomatosis in a non-small cell lung cancer patient with poor performance status | |
| Chen et al. | Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer | |
| EP3573644B1 (en) | Cell penetrating peptide inhibitors of p53-mdm2 interaction | |
| IT202100006494A1 (it) | N-palmitoil-etanolamide per l’uso nella prevenzione del carcinoma colo-rettale | |
| Belloumi et al. | An unusual clinical manifestation of a relapsed typical pulmonary carcinoϊd tumor | |
| Grabarnick et al. | PEGylated Liposomes Remotely Loaded with the Combination of Doxorubicin, Quinine, and Indocyanine Green Enable Successful Treatment of Multidrug-Resistant Tumors. Pharmaceutics 2021, 13, 2181 | |
| Helena et al. | PP01. 88 REZILIENT3: Phase 3 Study of Zipalertinib plus Chemotherapy in Previously Untreated, Advanced Nonsquamous NSCLC Patients with EGFR Exon 20 Insertions | |
| Shin et al. | Dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer: Real-world data and Insights | |
| Wu et al. | Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trial | |
| US20210000815A1 (en) | Pharmacokinetic enhancement of ezh2 inhibitors through combination therapies | |
| Kehayov et al. | Sacral nerve root metastasis in a patient with lung carcinoma resembling neurinoma–a case report and literature review | |
| WO2025250569A1 (en) | Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors | |
| EP4482528A2 (en) | A peptide from a photosynthetic bacterium directly targets mitochondria to trigger apoptosis in advanced prostate cancer cells |